{"id":872500,"date":"2025-08-07T07:58:08","date_gmt":"2025-08-07T11:58:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system\/"},"modified":"2025-08-07T07:58:08","modified_gmt":"2025-08-07T11:58:08","slug":"daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system\/","title":{"rendered":"Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System"},"content":{"rendered":"
\n

\n Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision<\/em>\n <\/p>\n

\n Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n
\n Daxor Corporation<\/u>
\n <\/a> (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA\u2122<\/sup> device quantifies a patient\u2019s blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year.<\/p>\n

\u201cFor decades, clinicians without access to BVA have been forced to estimate a patient\u2019s blood volume status using indirect, often invasive, or imprecise methods,\u201d said Michael Feldschuh, Daxor\u2019s President and CEO. \u201cThis critical knowledge gap has impacted treatment decisions across numerous medical specialties. Daxor\u2019s next generation BVA device changes the game by delivering even faster, precise blood volume data anywhere there is access to a laboratory\u2014from the hospital to the outpatient clinic.\u201d<\/p>\n

Volume derangement is a silent crisis driving a multi-billion annual healthcare burden. Conditions such as heart failure (over seven million patients and one million hospitalizations annually), critical care and sepsis (7.4 million admissions), dialysis, surgical blood loss, traumatic injury, and syncope all depend on accurate fluid management.<\/p>\n

\u201cOur diagnostic innovation is a game-changer for fluid management,\u201d said John L. Jefferies, MD, MPH, MBA, Daxor’s Chief Medical Officer. \u201cBy using the gold standard indicator tracer dilution technique, we can overcome the inaccuracies of traditional clinical assessments, especially in patients with multiple and complex conditions. BVA provides precise, objective data, empowering value-based care through better outcomes and fewer hospitalizations.\u201d<\/p>\n

In peer-reviewed studies, blood volume analysis guided care was associated with reduced heart failure one-year mortality by 86%<\/u><\/a>, (p<0.001). It also demonstrated shorter hospital stays<\/u><\/a>, 56% fewer readmissions,<\/u><\/a> and significantly lower healthcare costs<\/u><\/a>. Data from a randomized control trial in the ICU also showed significant benefit with BVA-guided care, lowering mortality by66%<\/u> in<\/a> a cohort of predominantly septic\/ARDS patients (p<0.03).<\/p>\n

Building upon the success of its predecessor, the Daxor BVA-100\u2122<\/sup> , this next generation analyzer redefines efficiency enabling far broader use in clinical settings where resources are limited:<\/p>\n